News
Economic Times
Oct 31, 2022
Eyestem bags the Top Innovator award : ET Startup Awards 2022
It’s estimated that cell therapy products will cost more than $450,000 per injection globally. The Bengaluru-based Eyestem’s mission to democratise access to such treatment by bringing the cost down to less than a 50th of that won it the Top Innovator Award at the ET Startup Awards 2022.
Times of India
Oct 26, 2022
How med-tech start-ups are leading the way towards a more robust healthcare infrastructure in India
The recent pandemic has exposed a whole lot of shortcomings in the healthcare system here in India. I believe the most important lesson that the pandemic has taught us is that healthcare delivery needs to be decentralised. This push towards the periphery will ensure that healthcare is available where it is needed most, when it is needed most.
The Hindu BusinessLine
Aug 31, 2022
Japanese fab manufacturer Renesas to acquire India’s fabless Steradian
Steradian Semiconductors, a Bengaluru-based fabless semiconductor company that providers 4D imaging radar solutions, is being acquired by Renesas Electronics Corporation, a Japanese firm that supplies advanced semiconductor solutions.
Economic Times
Aug 7, 2022
Eyestem raises Series A round from Biological E, Alkem and others
Eyestem, a Bengaluru-based cell therapy company, has raised $6.4 million (Rs 51 Crore) in a Series A round led by three pharma majors - Biological E. Limited (BE), Alkem, NATCO and Anurag and Karan Bagaria, promoters of Kemwell Biopharma. Existing investors Endiya Partners and Kotak Private Equity also participated in this round
2022 All rights reserved
